FOR ADULTS WITH PRIMARY IgAN AT RISK OF DISEASE PROGRESSION
"The ability to add FABHALTA to a stable dose of RASi and SGLT2i allows nephrologists to individualize the approach to each patient."
- Craig Gordon, MD, MS, is compensated for his time by Novartis.
FABHALTA targets the alternative complement pathway by binding to Factor B
WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA
FABHALTA, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type b. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.
Because of the risk of serious infections caused by encapsulated bacteria, FABHALTA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the FABHALTA REMS.
FABHALTA is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression.
Definitions
IgAN, immunoglobulin A nephropathy; MOA, mechanism of action; RASi, renin-angiotensin system inhibitor; SGLT2i, sodium/glucose cotransporter-2 inhibitor.
Reference
1. Fabhalta. Prescribing information. Novartis Pharmaceuticals Corp.